Skip to content

Effects of alpha lipoic acid supplementation on serum level of visfatin, markers of oxidative stress, inflammation and insulin resistance in patients with chronic renal failure undergoing hemodialysis.

Effects of alpha lipoic acid supplementation on serum level of visfatin, markers of oxidative stress, inflammation and insulin resistance in patients with chronic renal failure undergoing hemodialysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138806301197N2
Enrollment
60
Registered
2010-03-20
Start date
2010-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal failure. End-stage renal disease

Interventions

Sponsors

Nutritional Research Center Tabriz University Of Medical Science
Lead Sponsor
Vice Chancellor for Research, Tabriz University Of Medical Science
Collaborator
Drug Applied Research Center Tabriz University Of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: obtaining informed consent, being on hemodialysis for more than 6 months, receiving 3 times hemodialysis each week Exclusion criteria: hepatitis and other infections less than 20 years, receiving any NSAID and SAID, alpha lipoic acid supplement, vitamin C, vitamin E, valporic acid in the month prior to the study, presence of gastrointestinal disorders, being candidate for kidney transplantation, pregnancy or lactation, smoking, possibility of any side effect for consumption of the supplement

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Visfatin. Timepoint: baseline and after 8 weeks. Method of measurement: ELIZA.;TAC. Timepoint: baseline and after 8 weeks. Method of measurement: calorimetric method.;MDA. Timepoint: baseline and after 8 weeks. Method of measurement: flurimetric method.;HsCRP. Timepoint: baseline and after 8 weeks. Method of measurement: immunoturbidometric method.;Fasting insulin. Timepoint: baseline and after 8 weeks. Method of measurement: ELIZA.;Fasting Glu. Timepoint: baseline and after 8 weeks. Method of measurement: calorimetric method.;HOMA-IR. Timepoint: baseline and after 8 weeks. Method of measurement: formula.;Tchol. Timepoint: baseline and after 8 weeks. Method of measurement: calorimetric method.;Serum TG. Timepoint: baseline and after 8 weeks. Method of measurement: calorimetric method.;Serum HDL-c. Timepoint: baseline and after 8 weeks. Method of measurement: calorimetric method.;Serum LDL. Timepoint: baseline and after 8 weeks. Method of measurement: Friedelwald formula.;Body Mass Index (BMI). Timepoint: baseline and after 8 weeks. Method of measurement: calculation.;Total Daily Calorie. Timepoint: baseline and after 8 weeks. Method of measurement: 24h recalls.;Daily protein. Timepoint: baseline and after 8 weeks. Method of measurement: 24h recalls.;Daily Fat. Timepoint: baseline and after 8 weeks. Method of measurement: 24h recall.;Daily charbohydrate. Timepoint: baseline and after 8 weeks. Method of measurement: 24h recall.;Update 19 Feb 2011: serum albomin. Timepoint: Update 19 Feb 2011: baseline and after 8 weeks. Method of measurement: Update 19 Feb 2011: Bromocresol Green method.

Secondary

MeasureTime frame
Health benefits for patients. Timepoint: baseline and weekly monitoring. Method of measurement: observation and evaluation of biochemical parameters.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza mahdavi

Tabriz University Of Medical Sciences

mahdavir@tbzmed.ac.ir t.khabbazi@gmail.com+98 41 1335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026